pharmaphorum7y
Sunovion's COPD nebuliser approved in US
The US regulator has approved the first nebulised long-acting muscarinic antagonist for COPD from Sunovion, offering a device that allows patients to breathe normally while taking their medicine.
pharmaphorum7y
FDA rejects Sunovion's nebulised COPD drug
Sunovion hopes the twice-daily drug will become the first nebulised long-acting muscarinic antagonist for COPD, based on phase 3 data. But the company has competition from Theravance and Mylan.
Nature4y
A phenotypic high-throughput approach to neuropsychiatric drug discovery
This includes a novel compound known as SEP-363856, being developed by Sunovion Pharmaceuticals for schizophrenia, which is now in phase 3 clinical trials. The company has a 20-year history in ...
Warc2y
“Little Big Things” make big impression in Sunovion pre-launch campaign
senior director/multichannel marketing at Sunovion Pharmaceuticals. We’re long-term subscribers to WARC and it’s a tool we use extensively. We use it to source case studies and best practice for the ...
Nature2y
Industrializing behavioral testing to redefine neuropsychiatric drug discovery
Roche and Sunovion are among the drug developers to recognize the power of the platform, leading to clinical proof-of-concept data that have emboldened PsychoGenics to build an internal pipeline.
Medscape4y
Christoph U. Correll, MD
Sunovion; Supernus; Takeda; Teva Provided expert testimony for: Bristol-Myers Squibb; Janssen; Otsuka Serve(d) as a speaker for: Allergan; Angelini; Gedeon Richter; Janssen/J&J; Lundbeck ...